Marker Therapeutics, Inc. has announced a significant milestone in its clinical development journey by securing a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This funding will support the advancement of the company’s lead investigational MAR-T cell therapy, MT-601, in the planned Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma (LBCL).

The grant is pivotal for Marker Therapeutics, as it not only provides substantial non-dilutive funding but also reinforces the potential of MT-601 in treating patients who have limited therapeutic options following CAR-T therapy. This development is expected to enhance Marker’s competitive position in the pharmaceutical preparations sector, particularly in the field of immuno-oncology.

Background

Founded in Houston, Texas, Marker Therapeutics, Inc. (Ticker: MRKR) is a clinical-stage immuno-oncology company focused on developing multi-antigen recognizing (MAR)-T cell therapies. The company holds an exclusive worldwide license from Baylor College of Medicine and operates under the SIC code 2834, which pertains to pharmaceutical preparations. Marker has been active in the market with several recent filings, including an 8-K on November 19, 2026, and a 10-Q on November 16, 2026.

What the Filing Says

According to the recent filing, Marker Therapeutics stated, "On November 19, 2026, Marker Therapeutics, Inc. announced that it was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will be used to support the advancement of the Company’s lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study." This grant will help propel the company’s clinical efforts forward.

Impact

The grant is expected to have a significant impact on Marker Therapeutics, particularly as it aims to advance its MT-601 therapy through critical clinical trials. The funding will allow the company to build on the encouraging results from its Phase 1 APOLLO study, which demonstrated a 66% objective response rate among patients with heavily pretreated lymphoma. This could also influence other companies in the oncology space as they seek similar funding opportunities for their innovative therapies.

What's Next

Marker Therapeutics has indicated that it looks forward to providing updated clinical results later this year and advancing MT-601 through its next stage of clinical development. The filing does not specify the exact next steps, but the company is poised to leverage this grant to enhance its research and development efforts.